Revvity Signals is pleased to announce the final release of ChemBioOffice Enterprise (CBOE) version 23.1.3, marking a significant milestone in its long and successful journey. CBOE 23.1.3 is a cumulative minor release intended for installation solely on top of CBOE 23.1.1 or CBOE 23.1.2.
The focus of this release is adding Shopping Cart functionality to the ChemACX Explorer (cloud), Qualification of CDJS 23.11, CDAX 20.1.17 and CDWS 2.17. This release also provides compatibility with the latest version of Adobe Acrobat Pro/Reader Continuous Release (64-bit), MSO365 (32-bit), Oracle patches 19.26 and integration with E-Notebook 23.1.3. This release also includes fixes of the customer-reported and internally reported issues in several modules: Web Registration, Inventory, ChemACX, Security, DataLoaderNG, and INVLoader.
What’s New
- Added Shopping Cart functionality to the ChemACX Explorer (ChemACX Cloud version)
General
Support has been extended to:
- Latest patches of Adobe Acrobat Pro/Reader Continuous Release (64-bit)
- Latest patches of MSO 365 (32-bit)
- Oracle patches 19.26
- Integration with E-Notebook 23.1.3 (concurrent release)
- CDJS 23.11, CDWS 2.17 and CDAX 20.1.17
Upgrades Tested
This release applies to existing customers who have CBOE 23.1.1 and CBOE 23.1.2. Revvity Signals has specifically qualified the following:
- CBOE 23.1.1 to CBOE 23.1.3
- CBOE 23.1.2 to CBOE 23.1.3
Please refer to “CBOE 23.1.3 Installation Guide.pdf” for more details.
Location of Goods
The CBOE 23.1.3 installer, release notes, and installation guide are available on Flexera starting June 10, 2025, for both internal use and customer access.
As previously communicated, ChemBioOffice Enterprise has officially entered the sunset phase, and this release will be the last planned version of the product.
The End of Life (EOL) for ChemBioOffice Enterprise is scheduled for January 01, 2027. Until then, we will continue to provide customer support through a dedicated team, focusing on stability and critical issue resolution.
Comments
0 comments
Article is closed for comments.